Hence, the low affinity derivative of IL‐12 fused to a high affinity PD‐1 antibody preferentially activates tumor infiltrating PD1+ T cells, thus, eliciting robust antitumor activities in preclinical mouse models while exhibiting a beneficial toxicity profile (Zou et al. 2024). Here, PDCD1 is linked to neoplasm.